Related Experiment Video
Updated: Mar 5, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.4K
Medication Dosage in Overweight and Obese Children
Summary
Pediatric obesity presents challenges for medication dosing. This statement recommends weight-based dosing for children under 40 kg and pharmacokinetic analysis for overweight or obese children to ensure safe and effective medication use.
Area of Science:
- Pediatric pharmacology
- Obesity medicine
- Clinical pharmacy
Background:
- Over 31.8% of U.S. children (ages 2-19) are overweight or obese.
- Obesity complicates weight-based medication dosing (mg/kg) and pharmacokinetic predictions in pediatric patients.
- Altered body composition in obesity affects drug distribution (volume of distribution) and clearance, impacting efficacy and safety.
Purpose of the Study:
- To provide recommendations for medication dosing in overweight and obese pediatric patients.
- To address challenges in pediatric pharmacokinetics due to obesity.
- To minimize medication errors associated with weight-based dosing in children.
Main Methods:
- This is a position statement from the Pediatric Pharmacy Advocacy Group.
- Recommendations are based on current understanding of pharmacokinetic principles in pediatric obesity.
- Guidance is provided for different weight categories and consideration of adult doses.
Main Results:
- Recommends weight-based dosing for pediatric patients < 40 kg.
- Suggests using weight-based dosing for patients ≥ 40 kg, provided the adult dose is not exceeded.
- Advocates for pharmacokinetic analysis to adjust medication in overweight/obese children.
Conclusions:
- Standard weight-based dosing may be insufficient for overweight and obese children.
- Pharmacokinetic analysis is crucial for optimizing drug therapy in this population.
- Further research is needed to refine medication dosing strategies for pediatric obesity.
Related Concept Videos
01:21Drug Dosing: Obese Patients
320
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
320
01:29Drug Dosing: Infants and Children
555
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
555
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
331
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
331
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
342
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
342
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
503
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
503
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
259
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
259